Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of AMO-143 in preparation of medicines for treating long QT syndrome

A kind of AMO-143, 1. The technology of AMO-143 is applied in the field of application of AMO-143 in the preparation of drugs for the treatment of long QT syndrome, which can solve the problems such as inability to cure

Inactive Publication Date: 2015-12-23
NINGBO MEDICAL CENT LIHUILI HOSPITACL
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the treatment methods of LQTS mainly adopt drug therapy, left ventricular sympathetic denervation and implantation of cardioverter-defibrillator, but these methods have limitations and cannot cure the disease completely.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of AMO-143 in preparation of medicines for treating long QT syndrome
  • Application of AMO-143 in preparation of medicines for treating long QT syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] Materials and Methods

[0010] 1.1 Experimental instruments and reagents

[0011] 1.1.1 Main experimental instruments

[0012] Table 1 Names and manufacturers of experimental instruments

[0013]

[0014] 1.1.2 Experimental drugs and reagents

[0015] Table 2 Names and manufacturers of experimental drugs

[0016]

[0017] 1.2 Experimental method

[0018] real-time PCR

[0019] Total RNA was extracted from transfected U2OS cells with Trizol reagent. The RNA was subsequently treated with sterile RNase-free, and the level of hERG gene mRNA was assessed using Taqman probe and detected by qRT-PCR. Primers and probes were from ABI company cat. #4331182 (ID: Hs04234270-g1). Reverse transcription conditions were set as an initial step of 10 min at 95 °C followed by 40 cycles of 15 sec at 95 °C and a hold at 60 °C for 1 min. Real-time PCR reactions were performed in independent replicates three times. Results were analyzed using the 2-ΔΔCT relative quantification ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of AMO-143 in preparation of a pharmaceutical composition for preventing and treating a long QT syndrome and promoting hERG expression, and the pharmaceutical composition for treating the long QT syndrome. The pharmaceutical composition is characterized by containing the AMO-143.

Description

technical field [0001] The present invention relates to the application of AMO-143 in the preparation of medicine for treating long QT syndrome, more particularly, the present invention relates to the application of AMO-143 in preparing medicine for promoting hERG expression in the treatment of long QT syndrome. Background technique [0002] Long QT syndrome (LQTS) is a group of clinical syndromes caused by the dysfunction of myocardial membrane ion channels caused by mutations in the genes encoding cardiac ion channel proteins. Tachycardia (Torsadedepoints, TdP) and episodic syncope, SCD is characterized. LQTS caused by gene mutation is called congenital LQTS (congenital LongQTSyndrome, cLQTS), and acquired LQTS is called acquired LQTS (acquired LongQTSyndrome, aLQTS). Up to now, 13 genes have been found to be related to cLQTS. Among them, congenital long QT syndrome type 2 (LQT2) caused by hERG (huamnether-a-Go-Gorelatedgene, hERG) mutation accounts for 45% of the total m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K31/7105A61P9/06
Inventor 杨曦周建庆廉姜芳毛海燕黄晓燕
Owner NINGBO MEDICAL CENT LIHUILI HOSPITACL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com